Initiator Pharma A/S (STO: INIT)

Market Cap	459.61M
Revenue (ttm)	n/a
Net Income (ttm)	-18.42M
Shares Out	56.05M
EPS (ttm)	-0.34
PE Ratio	n/a
Forward PE	7.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,715
Open	8.00
Previous Close	8.10
Day's Range	7.75 - 8.25
52-Week Range	6.72 - 12.20
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 15, 2024

About Initiator Pharma

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes IPED2015, a drug candidate which is in clinical phase 2a for the treatment of organic erectile dysfunction; IP2018, a monoamine reuptake inhibitor completed Phase IIa for the treatment of psychogenic erectile dysfunction primarily targeting the serotonin followed by the dopamine system; and IPTN2021, a Phase 1 clinical drug program targeting an orphan drug indic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 3
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: INIT

Financial Performance

In 2023, ONCO's revenue was 35.22 million, an increase of 321.54% compared to the previous year's 8.36 million. Losses were -249.11 million, -26.29% less than in 2022.

Financial numbers in DKK